guest ::
| Home > Publications database > A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma. > print |
| Home > Publications database > A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma. > print |
| 001 | 304594 | ||
| 005 | 20251007135431.0 | ||
| 024 | 7 | _ | |a 10.1038/s41590-025-02268-7 |2 doi |
| 024 | 7 | _ | |a pmid:40954250 |2 pmid |
| 024 | 7 | _ | |a 1529-2908 |2 ISSN |
| 024 | 7 | _ | |a 1529-2916 |2 ISSN |
| 024 | 7 | _ | |a altmetric:181418885 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01917 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Andrade, Augusto Faria |0 0000-0001-5866-0501 |b 0 |
| 245 | _ | _ | |a A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma. |
| 260 | _ | _ | |a London |c 2025 |b Springer Nature Limited |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1759838035_6323 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:B310#LA:B310# / 2025 Oct;26(10):1794-1806 |
| 520 | _ | _ | |a Pediatric low-grade gliomas (pLGGs) are mitogen-activated protein kinase (MAPK) pathway-activated brain tumors prevalent in children and are associated with morbidity despite favorable survival. Here using imaging mass cytometry, we spatially characterized at the single-cell level the tumor microenvironment (TME) of 120 pLGG cases, considering age, molecular drivers, brain location and tumor subtype. Our analysis identified myeloid cells-including resident microglia and bone marrow-derived macrophages-as the predominant immune population in the TME, particularly in optic pathway tumors. Additionally, we discovered an immune signature predictive of progression-free survival. Spatial analysis identified specific cellular interactions, notably myeloid-myeloid contacts and macrophage-enriched regions harboring MAPK-activated, TIM-3+ myeloid cells, suggesting an immunosuppressive TME. Our study provides a comprehensive resource on the immune landscape of these pLGGs and underscores the immunosuppressive role of diverse myeloid infiltrates. These findings also indicate that combining TIM-3 blockade with MAPK inhibition might be a promising therapeutic strategy to target both the TME and oncogenic MAPK activation in pLGG tumors. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Sigaud, Romain |0 P:(DE-He78)a5e60710c7515b3e1de74ced6928a9dd |b 1 |e First author |u dkfz |
| 700 | 1 | _ | |a Puligandla, Evan |0 0000-0001-8449-9221 |b 2 |
| 700 | 1 | _ | |a Liu, Bridget |b 3 |
| 700 | 1 | _ | |a Karimi, Elham |b 4 |
| 700 | 1 | _ | |a Annett, Alva |0 0000-0002-3258-4296 |b 5 |
| 700 | 1 | _ | |a Rezanejad, Morteza |b 6 |
| 700 | 1 | _ | |a Jawhar, Wajih |0 0000-0002-2724-6401 |b 7 |
| 700 | 1 | _ | |a Taylor, Robert |b 8 |
| 700 | 1 | _ | |a Cao, Yi |0 0009-0000-7350-5681 |b 9 |
| 700 | 1 | _ | |a Schmid, Simone |0 P:(DE-He78)6e4a8cc4eb35e694f95453ed8a927a83 |b 10 |
| 700 | 1 | _ | |a Selt, Florian |0 P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e |b 11 |u dkfz |
| 700 | 1 | _ | |a Hernáiz Driever, Pablo |b 12 |
| 700 | 1 | _ | |a Horn, Svea |b 13 |
| 700 | 1 | _ | |a Sievers, Philipp |0 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6 |b 14 |u dkfz |
| 700 | 1 | _ | |a Prinz, Marco |0 0000-0002-0349-1955 |b 15 |
| 700 | 1 | _ | |a Glatzel, Markus |0 0000-0002-7720-8817 |b 16 |
| 700 | 1 | _ | |a Mawrin, Christian |b 17 |
| 700 | 1 | _ | |a Hartmann, Christian |b 18 |
| 700 | 1 | _ | |a Monoranu, Camelia-Maria |b 19 |
| 700 | 1 | _ | |a Konnikova, Liza |0 0000-0003-4804-5497 |b 20 |
| 700 | 1 | _ | |a Sahm, Felix |0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88 |b 21 |u dkfz |
| 700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 22 |u dkfz |
| 700 | 1 | _ | |a Witt, Olaf |0 P:(DE-He78)143af26de9d57bf624771616318aaf7c |b 23 |u dkfz |
| 700 | 1 | _ | |a Jones, David |0 P:(DE-He78)551bb92841f634070997aa168d818492 |b 24 |u dkfz |
| 700 | 1 | _ | |a Koch, Arend |b 25 |
| 700 | 1 | _ | |a Kleinman, Claudia L |b 26 |
| 700 | 1 | _ | |a Capper, David |0 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c |b 27 |u dkfz |
| 700 | 1 | _ | |a Walsh, Logan |0 0000-0001-8771-2577 |b 28 |
| 700 | 1 | _ | |a Jabado, Nada |0 0000-0003-2485-3692 |b 29 |
| 700 | 1 | _ | |a Milde, Till |0 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f |b 30 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1038/s41590-025-02268-7 |0 PERI:(DE-600)2026412-4 |n 10 |p 1794-1806 |t Nature immunology |v 26 |y 2025 |x 1529-2908 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:304594 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)a5e60710c7515b3e1de74ced6928a9dd |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)6e4a8cc4eb35e694f95453ed8a927a83 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 21 |6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 23 |6 P:(DE-He78)143af26de9d57bf624771616318aaf7c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 24 |6 P:(DE-He78)551bb92841f634070997aa168d818492 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 30 |6 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-13 |w ger |
| 915 | _ | _ | |a DEAL Nature |0 StatID:(DE-HGF)3003 |2 StatID |d 2024-12-13 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NAT IMMUNOL : 2022 |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-13 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-13 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-13 |
| 915 | _ | _ | |a IF >= 30 |0 StatID:(DE-HGF)9930 |2 StatID |b NAT IMMUNOL : 2022 |d 2024-12-13 |
| 920 | 2 | _ | |0 I:(DE-He78)B310-20160331 |k B310 |l KKE Pädiatrische Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B310-20160331 |k B310 |l KKE Pädiatrische Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)BE01-20160331 |k BE01 |l DKTK Koordinierungsstelle Berlin |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)B300-20160331 |k B300 |l KKE Neuropathologie |x 3 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 4 |
| 920 | 1 | _ | |0 I:(DE-He78)B360-20160331 |k B360 |l Pädiatrische Gliomforschung |x 5 |
| 920 | 0 | _ | |0 I:(DE-He78)B310-20160331 |k B310 |l KKE Pädiatrische Onkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B310-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)BE01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B300-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B360-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|